insulin secretagogues - sulfonylureas

systematic review meta-analysis network meta-analysis

Select diabetes type 2 All type of patient       sulfonylurea G1sulfonylurea G1 add on METsulfonylureas G2sulfonylureas G2 add on METsulfonylureas G3 add on insulinsulfonylureas G3 add on METsulfonylureas G3 monotherapy gliclazideglimepirideglimeripideglipizideglyburide vs placebovs gliclazidevs Sulfonylurea      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (1)myocardial infarction (fatal and non fatal) (1)stroke (fatal and non fatal) (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	myocardial infarction (fatal and non fatal)
diabetes type 2
gliclazide
Ristic, 2006	gliclazide	nateglinide (add on MET)			Low risk of bias	-
Matthews, 2005	gliclazide	pioglitazone (add on MET)			Low risk of bias	-
Khanolkar, 2008	gliclazide	rosiglitazone (add on MET)				-
glimepiride
Charpentier, 2001	glimepiride monotherapy	metformin			Low risk of bias	-
glimeripide
Schade, 1998	glimepiride	placebo			Low risk of bias	-
Kaneko, 1993	glimepiride	placebo				-
Luis Bautista, 2003	glimepiride	placebo			Low risk of bias	-
Rosenstock, 1996	glimepiride	placebo			Low risk of bias	-
Study 201 (Goldberg), 1996	glimepiride	placebo			Low risk of bias	-
Study 202	glimepiride	placebo				-
Riddle, 1994	glimepiride	placebo (add on insulin)				-
Charpentier, 2001	glimepiride	placebo (add on MET)			Low risk of bias	negative
LEAD-2 (Nauck) Sulf vs pbo, 2009      NCT	glimepiride	placebo (add on MET)			Low risk of bias	-
Draeger, 1996	glimepiride	glibenclamide			Low risk of bias	-
Protocol 311	glimepiride	glibenclamide				-
Charpentier (301F)	glimepiride	gliclazide				-
Inukai, 2005	glimepiride	gliclazide or glibenclamide				-
Sonnenberg, 1997	glimepiride od	glimepiride bid				-
Clark (301), 1997	glimepiride	glipizide				-
Dills, 1996	glimepiride	glyburide			Low risk of bias	-
glipizide
Goldstein	glipizide	control (add on MET)				-
Rosenstock, 1993	glipizide	glyburide				-
Birkeland, 1994	glipizide	glyburide				-
Birkeland, 1994	glipizide	glyburide			Low risk of bias	-
Testa, 1998	glipizide	placebo				-
Simonson, 1997	glipizide	placebo			Low risk of bias	-
Feinglos, 2005	glipizide GITS	placebo (add on MET)			Low risk of bias	-
Nauck, 2007	glipizide	sitagliptin (add on MET)				-
glyburide
Hermann, 1991	glibenclamide	c (add on MET)				-
DeFronzo, 1995	glyburide	c (add on MET)			Low risk of bias	-
Erle, 1999	glyburide	c (add on MET)				-
Marre (ass), 2002	glibenclamide	control (add on MET)			Low risk of bias	-
Tosi, 2003	glibenclamide	control (add on MET)			Low risk of bias	-
Blonde, 2002	glyburide	control (add on MET)			Low risk of bias	-
Garber, 2003	glyburide	control (add on MET)				-
Garber, 2002	glyburide	placebo			Low risk of bias	-
Vray, 1995	glyburide	placebo			Low risk of bias	-
Garber, 2006	glibenclamide	rosiglitazone (add on MET)			Low risk of bias	-